RxDoctor Payments Data

Himesh Sheth

Nephrology · Fairhaven, MANPI 1689060097

Payments from drug & device makers

$2,430in general payments, 2019–2025

Across 32 payments — averaging $75.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Calliditas Therapeutics US Inc.$250
  • Bayer$241
  • Travere Therapeutics, Inc.$225
  • Veloxis Pharmaceuticals, Inc.$125
  • Johnson & Johnson$125
  • plus $323 from 7 others

What the payments were for

  • Food & beverage$2,41499%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,430 in reported general payments places this provider in the 65th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$270,774
Medicare patients
506
Services billed
2,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin141$179,944
FarxigaDapagliflozin Propanediol16$24,123
OzempicSemaglutide14$21,054
Sevelamer Carbonate29$8,705
Cinacalcet Hcl19$1,351
Calcitriol97$1,059
Amlodipine Besylate103$950
Losartan Potassium99$908
Chlorthalidone22$627
Bumetanide38$573
Tamsulosin Hcl24$563
Doxazosin Mesylate19$414
Lisinopril65$404
Torsemide16$384
Furosemide77$346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,141$24,12316 claims
Novo NordiskOzempic$16$21,05414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 339 nephrology providers in Massachusetts.

Other nephrology in Fairhaven

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →